Oxford Genetics Ltd

oxfordgenetics.com

Oxford Genetics Ltd, a leader in synthetic biology, is a specialised contract research organisation offering services to support the discovery, development and production of biologics, gene and cell therapies. A unifying theme across the portfolio is expertise in designing DNA, optimising expression of proteins, cell line development, and improving viral delivery systems. Oxford Genetics is headquartered in Oxford, UK. For additional information, please visit our website.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy, Medical

OIAGEN STRENGTHENS HID WITH NGS TECHNOLOGIES BY ACQUIRING VEROGEN

QIAGEN | January 11, 2023

news image

QIAGEN recently announced its acquisition of Verogen, a leader in utilizing next-generation sequencing (NGS) technologies to advance the future of human identification (HID) and forensic investigation. QIAGEN, which introduced the first commercial kits to purify DNA from forensic casework samples in the late 1990s, is one of the leaders in the HID/forensics sector. Verogen, a privately-owned company launched in 2017, provides NGS tools and professional services to t...

Read More

Medical

REPLIGEN ANNOUNCES AGREEMENT TO ACQUIRE FLUID MANAGEMENT INNOVATOR METENOVA

GlobeNewswire | September 28, 2023

news image

Repligen Corporation a life sciences company focused on bioprocessing technology leadership, announced that it has entered into a definitive agreement to acquire privately-held Metenova AB (Metenova) of Mölndal, Sweden. Metenova is projected to generate revenues of $24 million to $25 million for fiscal year 2023, led by the success of its magnetic mixing and drive train technolog...

Read More

MedTech

ALLOY THERAPEUTICS ACQUIRES DEEPCDR BIOLOGICS TO BRING BIOINFORMATICS AND MACHINE LEARNING TO ITS ANTIBODY DISCOVERY OFFERING

Alloy Therapeutics | December 10, 2021

news image

Alloy Therapeutics, a biotechnology ecosystem company, announced it has acquired deepCDR Biologics, a Basel, Switzerland-based developer of deep learning technology for antibody discovery and optimization. The team and technology stack will form new bioinformatics and machine learning capabilities for Alloy and will be fully integrated into Alloy Discovery Services complementary workflow and processes. Alloy will expand the Basel deepCDR site as a permanent Alloy research facility and will hire ...

Read More

Industrial Impact

VERSANT VENTURES COLLABORATES WITH ABCELLERA TO ACCELERATE DRUG DEVELOPMENT FOR ITS PORTFOLIO OF BIOTECH COMPANIES

AbCellera and Versant Ventures | July 28, 2022

news image

AbCellera and Versant Ventures announced a multi-year collaboration to discover therapeutic antibodies for multiple targets selected by Versant’s portfolio of biologics-focused biotechs. Versant and AbCellera already have enabled three of the firm’s stealth-stage companies under previous partnerships. Under the terms of the deal, Versant portfolio companies will have rights to develop and commercialize the resulting therapeutic antibodies. AbCellera will receive resear...

Read More
news image

Cell and Gene Therapy, Medical

OIAGEN STRENGTHENS HID WITH NGS TECHNOLOGIES BY ACQUIRING VEROGEN

QIAGEN | January 11, 2023

QIAGEN recently announced its acquisition of Verogen, a leader in utilizing next-generation sequencing (NGS) technologies to advance the future of human identification (HID) and forensic investigation. QIAGEN, which introduced the first commercial kits to purify DNA from forensic casework samples in the late 1990s, is one of the leaders in the HID/forensics sector. Verogen, a privately-owned company launched in 2017, provides NGS tools and professional services to t...

Read More
news image

Medical

REPLIGEN ANNOUNCES AGREEMENT TO ACQUIRE FLUID MANAGEMENT INNOVATOR METENOVA

GlobeNewswire | September 28, 2023

Repligen Corporation a life sciences company focused on bioprocessing technology leadership, announced that it has entered into a definitive agreement to acquire privately-held Metenova AB (Metenova) of Mölndal, Sweden. Metenova is projected to generate revenues of $24 million to $25 million for fiscal year 2023, led by the success of its magnetic mixing and drive train technolog...

Read More
news image

MedTech

ALLOY THERAPEUTICS ACQUIRES DEEPCDR BIOLOGICS TO BRING BIOINFORMATICS AND MACHINE LEARNING TO ITS ANTIBODY DISCOVERY OFFERING

Alloy Therapeutics | December 10, 2021

Alloy Therapeutics, a biotechnology ecosystem company, announced it has acquired deepCDR Biologics, a Basel, Switzerland-based developer of deep learning technology for antibody discovery and optimization. The team and technology stack will form new bioinformatics and machine learning capabilities for Alloy and will be fully integrated into Alloy Discovery Services complementary workflow and processes. Alloy will expand the Basel deepCDR site as a permanent Alloy research facility and will hire ...

Read More
news image

Industrial Impact

VERSANT VENTURES COLLABORATES WITH ABCELLERA TO ACCELERATE DRUG DEVELOPMENT FOR ITS PORTFOLIO OF BIOTECH COMPANIES

AbCellera and Versant Ventures | July 28, 2022

AbCellera and Versant Ventures announced a multi-year collaboration to discover therapeutic antibodies for multiple targets selected by Versant’s portfolio of biologics-focused biotechs. Versant and AbCellera already have enabled three of the firm’s stealth-stage companies under previous partnerships. Under the terms of the deal, Versant portfolio companies will have rights to develop and commercialize the resulting therapeutic antibodies. AbCellera will receive resear...

Read More